Profile
Sector:
HealthcareIndustry:
Health Information ServicesCountry:
United StatesIPO:
11 December 2020Website:
http://www.certara.comNext earnings report:
09 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Wed, 03 Jul 2024 17:01:22 GMTDividend
Analysts recommendations
Institutional Ownership
CERT Latest News
RADNOR, Pa., July 02, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that it will release financial results for the second quarter of 2024 after the market close on Tuesday, August 6th, 2024. Company management will host a conference call to discuss financial results at 5:00PM ET.
RADNOR, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference.
Certara Inc. (CERT) Q4 2023 Earnings Call Transcript
Certara, Inc. (CERT) came out with quarterly earnings of $0.09 per share, missing the Zacks Consensus Estimate of $0.11 per share. This compares to earnings of $0.16 per share a year ago.
Certara Inc. (NASDAQ:CERT ) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants David Deuchler - Investor Relations William Feehery - Chief Executive Officer John Gallagher - Chief Financial Officer Conference Call Participants Jeff Garro - Stephens Inc David Windley - Jefferies Mike Ryskin - Bank of America Max Smock - William Blair Joe Vruwink - Baird Vikram Purohit - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Certara Third Quarter 2023 Earnings Conference Call.
Certara, Inc. (CERT) came out with quarterly earnings of $0.11 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.10 per share a year ago.
Certara, Inc. provides biosimulation software and services to the biotech and biopharma industry. The company is enjoying sales growth from its software division in the mid-teen but service growth is lagging. Analysts have mixed opinions on Certara's prospects even as the company is expanding its AI capabilities. An updated analysis is provided in the paragraphs below.
Certara Inc. CERT, -2.56% stock was down 14.6% in premarket trades on Thursday after the biotech software company missed Wall Street's adjusted earnings and revenue targets and said its 2023 profit would fall short of analyst forecasts. The company's second-quarter adjusted profit of 12 cents a share missed the FactSet consensus estimate of 13 cents a share, while its revenue of $90.5 million fell short of the analyst target of $92.2 million.
Certara Inc. (NASDAQ:CERT ) Q2 2023 Results Conference Call August 9, 2023 5:00 PM ET Company Participants David Deuchler - IR William Feehery - CEO and Director John Gallagher - Chief Financial Officer Conference Call Participants David Windley - Jefferies Vikram Purohit - Morgan Stanley Jeff Garro - Stephens Inc Kyle Crews - Credit Suisse Financial Services Max Smock - William Blair Gaurav Goparaju - Berenberg Capital Markets Joe Vruwink - Baird Operator Good day, and thank you for standing by. Welcome to the Certara Second Quarter 2023 Earnings Call.
PRINCETON, N.J., June 02, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Jefferies Global Healthcare Conference.
What type of business is Certara?
Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosimulation, empirical biosimulation, drug development and regulatory strategy, clinical pharmacology, model-based meta-analysis, regulatory writing and medical communications, regulatory operations, and market access. Further, company offers software, comprising mechanistic biosimulation platform, empirical PK/PD biosimulation platform, data standardization and compliance software, scientific informatics platform, clinical outcomes databases for biosimulation, authoring and management of regulatory submissions platform, and market access communication platform. The company serves biopharmaceutical companies, and academic and government institutions. It has operations in the United States, Canada, Spain, Luxembourg, Portugal, the United Kingdom, Germany, France, the Netherlands, Denmark, Switzerland, Italy, Poland, Japan, the Philippines, India, Australia, and China. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.
What sector is Certara in?
Certara is in the Healthcare sector
What industry is Certara in?
Certara is in the Health Information Services industry
What country is Certara from?
Certara is headquartered in United States
When did Certara go public?
Certara initial public offering (IPO) was on 11 December 2020
What is Certara website?
https://www.certara.com
Is Certara in the S&P 500?
No, Certara is not included in the S&P 500 index
Is Certara in the NASDAQ 100?
No, Certara is not included in the NASDAQ 100 index
Is Certara in the Dow Jones?
No, Certara is not included in the Dow Jones index
When does Certara report earnings?
The next expected earnings date for Certara is 09 August 2024